Xcout Intel
Carmine Therapeutics, Inc.
Carmine Therapeutics, Inc. is an EVX Ventures company headquartered in Cambridge, Massachusetts, focused on developing novel gene therapies.
Subscribe to see Carmine Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Carmine Therapeutics, Inc. at a glance
Carmine Therapeutics, Inc. is a biotechnology company headquartered in United States. It has raised at least $17.1M across the 3 funding rounds on record, 2 of them with a disclosed amount. Its most recent funding round, Series A, closed in October 2022. Xcout tracks 4 named people at Carmine Therapeutics, Inc., including Tenzin Gocha, Ph.D. (President).
Carmine Therapeutics, Inc. leadership
- Tenzin Gocha, Ph.D.President
- XQ LinCo-Founder & Chairman
- Prof. Harvey LodishScientific Co-Founder & Board Member
- Elan EzicksonDirector
Carmine Therapeutics, Inc. funding rounds
At least $17.1M raised across the 3 rounds on record (2 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | Undisclosed | — | |
| SEC Form D filing | $13.7M | — | |
| — | $3.4M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Carmine Therapeutics, Inc. competitors
A few of Carmine Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Verve Therapeutics, Inc. is a biotechnology company headquartered in Boston, Massachusetts, dedicated to pioneering single-course gene editing medicines for cardiovascular disease.
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
Exsilio Therapeutics Inc. is a biotechnology company headquartered in Boston, Massachusetts, founded in 2022 to pioneer genomic medicines and advanced genetic therapies.
Kelonia Therapeutics, Inc. is a clinical-stage biotech company headquartered in Boston, Massachusetts, focused on delivering genetic medicine for patients.
SparingVision is a genomic and gene therapy medicines company translating pioneering science into vision-saving treatments, with US headquarters located in Boston, Massachusetts.
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
Get Carmine Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Carmine Therapeutics, Inc.? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Carmine Therapeutics, Inc. in Xcout Intel
- 4 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access